Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Big cells, bigger BTK resistance in mantle cell lymphoma

Justin Taylor

Blood (2025) 146 (21): 2500–2501.

https://doi.org/10.1182/blood.2025029937

Published: 2025

Journal Articles

Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation

Blood (2025) 146 (Supplement 1): 2102.

https://doi.org/10.1182/blood-2025-2102

Published: 2025

Journal Articles

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes

Blood (2025) 146 (Supplement 1): 2518.

https://doi.org/10.1182/blood-2025-2518

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series

Erica Lamkin, Shai Shimony, Shefali Mehra, Andrew Lane, Justin Taylor

Blood (2025) 146 (Supplement 1): 6401.

https://doi.org/10.1182/blood-2025-6401

Published: 2025

Journal Articles

Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients

Katarina Micin, Ellen Madarang, Tiffany Nong, Maurizio Affer, Kiana Robles, Felipe Novoa, Sion Williams, Ana Ayupe, Yi Zhou, Justin Watts, Justin Taylor

Blood (2025) 146 (Supplement 1): 280.

https://doi.org/10.1182/blood-2025-280

Published: 2025

Journal Articles

Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors

Mina Tayari, Tulasigeri Totiger, Felipe Beckedorff, Adnan Mookhtiar, Anna Lesley Kingham, Gloria Mas Martin, Hsuan-Ting Huang, Efe Karaca, Daniel Bilbao, Justin Taylor, Ramin Shiekhattar, Justin Watts

Blood (2025) 146 (Supplement 1): 3292.

https://doi.org/10.1182/blood-2025-3292

Published: 2025

Journal Articles

XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53 -mutated myeloid malignancies

Blood (2025) 146 (18): 2244–2258.

https://doi.org/10.1182/blood.2025028803

Published: 2025

Includes: Supplemental data

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

Mikkael A. Sekeres, Sangeetha Venugopal, Namrata S. Chandhok, Justin M. Watts, Terrence Bradley, Justin Taylor, David Sallman, Zhuoer Xie, Eric Padron, Shelby Sullivan, Emily Zyborowicz, Jeffrey Carter, Cherilyn Heggen, Lindsay Gurska, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 3679.

https://doi.org/10.1182/blood-2024-203444

Published: 2024

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Blood (2024) 144 (Supplement 1): 2870.

https://doi.org/10.1182/blood-2024-210872

Published: 2024

Journal Articles

Genomic Proximity Mapping (GPM): Evaluation of a Next Generation Cytogenomic Assay for Improved Risk Stratification in Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 6157.

https://doi.org/10.1182/blood-2024-211570

Published: 2024

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2024) 144 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2024-193966

Published: 2024

Journal Articles

Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML

Katarina Micin, Tiffany Nong, Ellen Madarang, Kiana Robles, Maurizio Affer, Brittney Otero, Azad Gucwa, Felipe Novoa, Sion Williams, Ana Ayupe, Yi Zhou, Justin M. Watts, Justin Taylor

Blood (2024) 144 (Supplement 1): 4333.

https://doi.org/10.1182/blood-2024-207400

Published: 2024

Journal Articles

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Mikkael A. Sekeres, Hetty E. Carraway, Richard M Stone, Yazan F Madanat, Rami S. Komrokji, Sangeetha Venugopal, Namrata S. Chandhok, Terrence Bradley, Justin Taylor, Anastasia Santiago, Alessia Zoso, Justin M. Watts, Amy E. DeZern

Blood (2024) 144 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2024-203965

Published: 2024

Journal Articles

E7820, an Anti-Cancer Sulfonamide, in Combination with Venetoclax in Patients with Splicing Factor Mutant Myeloid Malignancies: A Phase II Clinical Trial

Jan Philipp Bewersdorf, Namrata Sonia Chandhok, Justin M. Watts, Andriy Derkach, Omar Abdel-Wahab, Eytan M. Stein, Justin Taylor

Blood (2023) 142 (Supplement 1): 1547.

https://doi.org/10.1182/blood-2023-182369

Published: 2023

Journal Articles

Altered RNA Export in SF3B1 Mutants Increases Sensitivity to Nuclear Export Inhibition

Sana Chaudhry, Felipe Beckedorff, Tulasigeri M Totiger, Maurizio Affer, Nidhi Hariramani, Skye Montoya, Alyssa Cornista, Daniel Bilbao, Evan R. Roberts, Jumana Afaghani, Jose Antonio Rodríguez, Eric Wang, Justin Taylor

Blood (2023) 142 (Supplement 1): 44.

https://doi.org/10.1182/blood-2023-182877

Published: 2023

Journal Articles

The LSD1 Inhibitor Ory-1001 (ladademstat) in Combination with Menin Inhibitor SNDX-5613 (revumenib) Has Synergistic in Vitro Activity in KMT2A -Rearranged AML Models

Mina M. Tayari, Tulasigeri M Totiger, Ramin Shiekhattar, Justin Taylor, Justin M. Watts

Blood (2023) 142 (Supplement 1): 5691.

https://doi.org/10.1182/blood-2023-190309

Published: 2023

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2023) 142 (Supplement 1): 6740.

https://doi.org/10.1182/blood-2023-180939

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Big cells, bigger BTK resistance in mantle cell lymphoma

Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series

Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients

Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors

XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53 -mutated myeloid malignancies

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Risk prediction for clonal cytopenia: multicenter real-world evidence

Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Genomic Proximity Mapping (GPM): Evaluation of a Next Generation Cytogenomic Assay for Improved Risk Stratification in Acute Myeloid Leukemia

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

E7820, an Anti-Cancer Sulfonamide, in Combination with Venetoclax in Patients with Splicing Factor Mutant Myeloid Malignancies: A Phase II Clinical Trial

Altered RNA Export in SF3B1 Mutants Increases Sensitivity to Nuclear Export Inhibition

The LSD1 Inhibitor Ory-1001 (ladademstat) in Combination with Menin Inhibitor SNDX-5613 (revumenib) Has Synergistic in Vitro Activity in KMT2A -Rearranged AML Models

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only